Shenyang Northern Hospital
Listed for 1 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Shenyang Northern Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Other diseases
Coronary heart disease
冠心病4 hospitals in Shenyang for coronary heart disease231 hospitals in China for coronary heart disease
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPrecision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
- Phase
- Phase 4
- Started
- 2026-06
- Posted
- Registry
- NCT07362966
Age 40 years to 85 years (registered criteria)
Led by Shenyang Northern HospitalShenyang
- RecruitingClinical Outcomes of Patients With Coronary Artery Disease
- Phase
- Not given
- Started
- 2024-02
- Posted
- Registry
- NCT06216847
Age 18 years to Not stated (registered criteria)
Led by Shenyang Northern HospitalShenyang
- Not yet recruitingSafety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07374718
Age 18 years to Not stated (registered criteria)
Led by Shenyang Northern HospitalShenyang
- Not yet recruitingOptimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07354828
Age 18 years to Not stated (registered criteria)
Led by Shenyang Northern HospitalShenyang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status18
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
- Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
- Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
- Clinical Outcomes of Patients With Coronary Artery Disease
- CHD Patient's Concern on Cardiac Rehabilitation
- Dabigatran Versus Warfarin With NVAF Who Undergo PCI
- The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease
- Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
- Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease
- Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI)
- Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease
- Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
- Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
- Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
- EXCEL-II DES to Treat the Patients With de Novo Coronary Artery Lesions. (CREDIT-III)
- EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.
- A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions
- The EVOLVE China Clinical Trial
Getting in touch
Name card to show staff or a driver
Shenyang Northern Hospital
沈阳
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.